Sitravatinib

Summary

Sitravatinib (CHEMBL3989926) is a phase-3 clinical-stage small molecule (ATC L01EX26) targeting PDGFRA, KIT, and FLT3; indicated across 18 conditions including neoplasm and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01EX26
• Targets: 12 (PDGFRA, KIT, FLT3…)
• Indications: 18 conditions
• Clinical trials: 34
• Chemistry: 629.7 Da · C33H29F2N5O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989926
Name	Sitravatinib
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	25212148
ATC	L01EX26
Molecular formula	C33H29F2N5O4S
Molecular weight	629.7
InChIKey	WLAVZAAODLTUSW-UHFFFAOYSA-N

SMILES: COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F

IUPAC name: 1-N’-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Also known as: MG-516, MG-91516, MGCD-516, MGCD516, Sitravatinib, SITRAVATINIB

Parent form; salt/anhydrous children: CHEMBL4298164

Patent coverage: 396 distinct patent families (982 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 906 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PDGFRA	platelet derived growth factor receptor alpha	Inhibition	7.52	6.2%	P16234
KIT	KIT proto-oncogene, receptor tyrosine kinase	Inhibition	8.22	0.5%	P10721
FLT3	fms related receptor tyrosine kinase 3	Inhibition	8.1	0.9%	P36888
FLT1	fms related receptor tyrosine kinase 1	Inhibition	8.22	0.1%	P17948
KDR	kinase insert domain receptor	Inhibition	8.3	1.1%	P35968
FLT4	fms related receptor tyrosine kinase 4	Inhibition	8.7	0.2%	P35916
MET	MET proto-oncogene, receptor tyrosine kinase	Inhibition	7.7	2.4%	P08581
NTRK1	neurotrophic receptor tyrosine kinase 1	Inhibition	8.3	0.1%	P04629
EPHA3	EPH receptor A3	Inhibition	9	0.4%	P29320
AXL	AXL receptor tyrosine kinase	Inhibition	8.82	1.1%	P30530
MERTK	MER proto-oncogene, tyrosine kinase	Inhibition	8.7	0.6%	Q12866
DDR2	discoidin domain receptor tyrosine kinase 2	Inhibition	9.3	0%	Q16832

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Mast/stem cell growth factor receptor Kit, Receptor-type tyrosine-protein kinase FLT3, Vascular endothelial growth factor receptor 2, High affinity nerve growth factor receptor, Hepatocyte growth factor receptor, Tyrosine-protein kinase receptor UFO, BDNF/NT-3 growth factors receptor.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
AXL	8.82	IC50	1.5	nM	CHEMBL_ACT_18946682
KDR	8.3	IC50	5	nM	CHEMBL_ACT_18772571
KDR	8.3	IC50	5	nM	CHEMBL_ACT_18946681
NTRK1	8.3	IC50	5	nM	CHEMBL_ACT_18946684
KIT	8.22	IC50	6	nM	CHEMBL_ACT_18946679
FLT3	8.1	IC50	8	nM	CHEMBL_ACT_18946680
NTRK2	8.05	IC50	9	nM	CHEMBL_ACT_18946683
MET	7.7	IC50	20	nM	CHEMBL_ACT_18772566

Target pathways

Aggregated over 12 target gene(s): PDGFRA, KIT, FLT3, FLT1, KDR, FLT4, MET, NTRK1, EPHA3, AXL, MERTK, DDR2.

Top Reactome pathways

122 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	4	FLT3, KIT, MET, PDGFRA
Constitutive Signaling by Aberrant PI3K in Cancer	4	FLT3, KIT, MET, PDGFRA
RAF/MAP kinase cascade	4	FLT3, KIT, MET, PDGFRA
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	4	FLT3, KIT, MET, PDGFRA
VEGF binds to VEGFR leading to receptor dimerization	3	FLT1, FLT4, KDR
Developmental Biology	2	KIT, MET
Signal Transduction	2	KIT, MET
Disease	2	KIT, MET
Neuropilin interactions with VEGF and VEGFR	2	FLT1, KDR
Negative regulation of the PI3K/AKT network	2	KIT, MET
Generic Transcription Pathway	2	KIT, MET
PI3K/AKT Signaling in Cancer	2	KIT, MET
VEGFA-VEGFR2 Pathway	2	AXL, KDR
Diseases of signal transduction by growth factor receptors and second messengers	2	KIT, MET
MAPK family signaling cascades	2	KIT, MET
MAPK1/MAPK3 signaling	2	KIT, MET
RNA Polymerase II Transcription	2	KIT, MET
Gene expression (Transcription)	2	KIT, MET
Intracellular signaling by second messengers	2	KIT, MET
Signaling by Receptor Tyrosine Kinases	2	KIT, MET
MITF-M-regulated melanocyte development	2	KIT, MET
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	2	FLT4, KDR
Dengue Virus Attachment and Entry	2	AXL, MERTK
Hemostasis	1	MERTK
PI3K Cascade	1	FLT3
Signaling by SCF-KIT	1	KIT
Regulation of KIT signaling	1	KIT
PLC-gamma1 signalling	1	NTRK1
Signalling to RAS	1	NTRK1
Frs2-mediated activation	1	NTRK1

Dominant GO biological processes

GO term	Targets
cell surface receptor protein tyrosine kinase signaling pathway	12
protein phosphorylation	12
cell migration	9
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	9
peptidyl-tyrosine phosphorylation	8
protein autophosphorylation	8
positive regulation of cell population proliferation	7
positive regulation of cell migration	5
positive regulation of ERK1 and ERK2 cascade	5
positive regulation of MAPK cascade	5
negative regulation of apoptotic process	5
signal transduction	4
spermatogenesis	4
vascular endothelial growth factor signaling pathway	4
cell differentiation	4

Indications & clinical

Indications

18 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
adenocarcinoma	2	MONDO:0004970	EFO:0000228
clear cell renal carcinoma	2	MONDO:0005005	EFO:0000349
liposarcoma	2	MONDO:0005060	EFO:0000569
squamous cell carcinoma	2	MONDO:0005096	EFO:0000707
breast neoplasm	2	MONDO:0021100	MONDO:0007254
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
melanoma	2	MONDO:0005105	EFO:0000756
esophageal squamous cell carcinoma	2	MONDO:0005580	EFO:0005922
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
liver disorder	1	MONDO:0005154	EFO:0001421
oral cavity squamous cell carcinoma	0	MONDO:0004958	EFO:0000199

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 34.

Phase distribution

Phase	Trials
PHASE2	17
PHASE1	9
PHASE3	4
PHASE1/PHASE2	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04164199	PHASE3	ACTIVE_NOT_RECRUITING	Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
NCT03906071	PHASE3	COMPLETED	Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04887870	PHASE2/PHASE3	COMPLETED	Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
NCT04921358	PHASE3	TERMINATED	Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT05564338	PHASE3	WITHDRAWN	Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
NCT05407519	PHASE2	RECRUITING	A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
NCT02664935	PHASE2	COMPLETED	National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT02954991	PHASE2	TERMINATED	Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT02978859	PHASE2	COMPLETED	Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
NCT03015740	PHASE1/PHASE2	COMPLETED	Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
NCT03606174	PHASE2	TERMINATED	A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
NCT03680521	PHASE2	COMPLETED	Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
NCT03941873	PHASE1/PHASE2	COMPLETED	A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
NCT04123704	PHASE2	TERMINATED	Sitravatinib in Metastatic Breast Cancer
NCT04727996	PHASE2	UNKNOWN	Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
NCT04734262	PHASE2	UNKNOWN	A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT04904302	PHASE2	TERMINATED	Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
NCT04925986	PHASE2	TERMINATED	Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
NCT05104801	PHASE2	UNKNOWN	Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
NCT05176925	PHASE2	TERMINATED	Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
NCT05228496	PHASE2	UNKNOWN	A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
NCT05419817	PHASE2	WITHDRAWN	Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
NCT05461794	PHASE2	TERMINATED	Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
NCT05614453	PHASE2	WITHDRAWN	Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
NCT02219711	PHASE1	COMPLETED	Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
NCT03666143	PHASE1	COMPLETED	A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT04472650	PHASE1	COMPLETED	Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
NCT04518046	PHASE1	COMPLETED	Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
NCT04772612	PHASE1	COMPLETED	A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04800614	PHASE1	COMPLETED	A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
NCT04887194	PHASE1	COMPLETED	PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
NCT04935112	PHASE1	COMPLETED	A Study to Explore the Effect of Acid-reducing Agents
NCT05255276	PHASE1	COMPLETED	PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
NCT03575598	EARLY_PHASE1	COMPLETED	Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

280 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
AXITINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
Crizotinib	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
FEDRATINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
Gefitinib	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
SORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
SUNITINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
NINTEDANIB	ChEMBL	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
LESTAURTINIB	ChEMBL	Phase 3	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
LINIFANIB	ChEMBL	Phase 3	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
FORETINIB	ChEMBL	Phase 2	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
R-406	ChEMBL	Phase 2	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
SU-014813	ChEMBL	Phase 2	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
TOZASERTIB	ChEMBL	Phase 2	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
Selumetinib	PubChem	Approved	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
ERLOTINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, PDGFRA
MIDOSTAURIN	ChEMBL + PubChem	Phase 4 (approved)	AXL, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
QUIZARTINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, NTRK1, PDGFRA
VANDETANIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, PDGFRA
CEDIRANIB	ChEMBL	Phase 3	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, PDGFRA
REBASTINIB	ChEMBL	Phase 2	AXL, DDR2, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
Idelalisib	PubChem	Approved	AXL, DDR2, EPHA3, FLT1, FLT3, FLT4, KIT, MERTK, MET, NTRK1, PDGFRA
CABOZANTINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, FLT1, FLT3, FLT4, KDR, KIT, MERTK, MET, NTRK1
DOVITINIB	ChEMBL	Phase 3	AXL, DDR2, FLT1, FLT3, FLT4, KDR, KIT, MERTK, NTRK1, PDGFRA
DORAMAPIMOD	ChEMBL	Phase 2	DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MERTK, NTRK1, PDGFRA
TANDUTINIB	ChEMBL	Phase 2	AXL, DDR2, FLT1, FLT3, FLT4, KDR, KIT, MERTK, NTRK1, PDGFRA
BOSUTINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT3, KIT, MERTK, MET, NTRK1, PDGFRA
ENTRECTINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, FLT1, FLT3, FLT4, KDR, KIT, MET, NTRK1
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	DDR2, FLT1, FLT3, FLT4, KDR, KIT, MET, NTRK1, PDGFRA
TIVOZANIB	ChEMBL + PubChem	Phase 4 (approved)	DDR2, EPHA3, FLT1, FLT3, FLT4, KDR, KIT, MET, PDGFRA
BMS-777607	ChEMBL	Phase 2	AXL, DDR2, FLT3, KDR, KIT, MERTK, MET, NTRK1, PDGFRA
DEFOSBARASERTIB	ChEMBL	Phase 2	AXL, DDR2, FLT1, FLT3, FLT4, KDR, KIT, MET, PDGFRA
ILORASERTIB	ChEMBL	Phase 2	AXL, FLT1, FLT3, FLT4, KDR, KIT, MET, NTRK1, PDGFRA
DASATINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, DDR2, EPHA3, FLT1, FLT3, KDR, KIT, PDGFRA
CANERTINIB	ChEMBL	Phase 3	AXL, EPHA3, FLT1, FLT3, KDR, KIT, MET, PDGFRA
CENISERTIB	ChEMBL	Phase 2	AXL, FLT1, FLT3, FLT4, KDR, KIT, MET, PDGFRA
OSI-632	ChEMBL	Phase 2	AXL, DDR2, FLT1, FLT3, FLT4, KDR, MET, PDGFRA
RAF-265	ChEMBL	Phase 2	DDR2, FLT1, FLT3, FLT4, KDR, KIT, MET, PDGFRA
PONATINIB	ChEMBL + PubChem	Phase 4 (approved)	DDR2, FLT1, FLT3, KDR, KIT, NTRK1, PDGFRA
INFIGRATINIB	ChEMBL	Phase 4 (approved)	FLT1, FLT3, FLT4, KDR, KIT, MET, PDGFRA
AT-9283	ChEMBL	Phase 2	FLT1, FLT3, FLT4, KDR, MERTK, MET, PDGFRA
BEMCENTINIB	ChEMBL	Phase 2	AXL, FLT3, KDR, KIT, MERTK, MET, PDGFRA
MERESTINIB	ChEMBL	Phase 2	AXL, DDR2, FLT3, KDR, MERTK, MET, NTRK1
MK-2461	ChEMBL	Phase 2	FLT1, FLT3, FLT4, KDR, MERTK, MET, NTRK1
BRIGATINIB	ChEMBL + PubChem	Phase 4 (approved)	EPHA3, FLT3, FLT4, KDR, KIT, MET
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	DDR2, EPHA3, FLT3, KDR, KIT, PDGFRA
NERATINIB	ChEMBL + PubChem	Phase 4 (approved)	AXL, EPHA3, FLT3, KDR, MERTK, MET
PEXIDARTINIB	ChEMBL + PubChem	Phase 4 (approved)	DDR2, FLT1, FLT3, KDR, KIT, PDGFRA
CERITINIB	ChEMBL	Phase 4 (approved)	FLT3, KDR, KIT, MET, NTRK1, PDGFRA
LENVATINIB	ChEMBL	Phase 4 (approved)	DDR2, FLT1, FLT4, KDR, KIT, PDGFRA
ALVOCIDIB	ChEMBL	Phase 3	AXL, EPHA3, FLT3, KIT, MERTK, PDGFRA
MOTESANIB	ChEMBL	Phase 3	FLT1, FLT3, FLT4, KDR, KIT, PDGFRA
SEMAXANIB	ChEMBL	Phase 3	FLT1, FLT3, FLT4, KDR, KIT, PDGFRA
CEP-32496	ChEMBL	Phase 2	DDR2, FLT1, FLT3, KDR, KIT, MET
DANUSERTIB	ChEMBL	Phase 2	DDR2, FLT3, FLT4, KDR, KIT, NTRK1
ENMD-2076	ChEMBL	Phase 2	DDR2, FLT3, KDR, KIT, NTRK1, PDGFRA
GLESATINIB	ChEMBL	Phase 2	AXL, DDR2, FLT3, KDR, MERTK, MET
PELITINIB	ChEMBL	Phase 2	AXL, EPHA3, FLT3, KDR, MERTK, MET
Binimetinib	PubChem	Approved	DDR2, FLT3, KDR, MERTK, MET, NTRK1